PM

PMV Pharmaceuticals IncNASDAQ PMVP Stock Report

Last reporting period 31 Dec, 2023

Updated 14 Nov, 2024

Last price

Market cap $B

0.077

Micro

Exchange

XNAS - Nasdaq

PMVP Stock Analysis

PM

Uncovered

PMV Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.077

Dividend yield

Shares outstanding

45.773 B

PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. The company is headquartered in Cranbury, New Jersey and currently employs 62 full-time employees. The company went IPO on 2020-09-25. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The firm is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.

View Section: Eyestock Rating